جامعة المعرفة
المصدر المعتمد للمعلومات البحثية والمخرجات هو قاعدة بيانات سكوبس (Elsevier Scopus) مع تدقيق بيانات الباحثين من عمادة البحث العلمي.
SA

Sama Abdullah Alanazi

بانتظار توثيق الانتساب2026–2026
2وثائق Scopus
0استشهاداً
0مؤشر h
0منها بانتماء الجامعة
إجمالي Scopus (كل الجهات)
مراجعةمفتوح (مستودع)2026

Comparative Efficacy and Safety of Intranasal Opioids versus Intravenous Morphine for Acute Moderate-to-Severe Pain: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Journal of Emergency Medicine

Background Intranasal (IN) opioids may provide non-invasive analgesia without delays associated with intravenous (IV) access, but their efficacy and safety versus IV morphine remain uncertain. Objectives To synthesize randomized evidence comparing IN opioids with IV morphine for acute moderate-to-severe pain. Methods PubMed, Scopus, Web of Science, and the Cochrane Library were searched from inception to May 2026 for randomized controlled trials (RCTs) in adults or children with acute moderate-to-severe pain in emergency, prehospital, procedural, or postoperative settings. Eligible trials directly compared IN opioids with IV morphine. The primary outcome was change in pain score from baseline at 20 and 30 minutes. Secondary outcomes included rescue analgesia and adverse events. Outcomes were pooled as standardized mean differences (SMD) or risk ratios (RR) using random-effects models. Results Ten RCTs involving 1,164 participants were included. IN opioids showed comparable analgesic efficacy to IV morphine at 20 minutes (SMD = −0.05, 95% CI: −0.24 to 0.14; p = 0.59; I² = 11.94%) and 30 minutes (SMD = −0.05, 95% CI: −0.24 to 0.15; p = 0.64; I² = 0.00%). Rescue analgesia was comparable (RR = 1.00, 95% CI: 0.81 to 1.25; p = 0.98). No significant differences were observed in overall adverse events, serious adverse events, respiratory complications, hypotension, gastrointestinal events, dizziness, or rhinorrhea. Dysgeusia was borderline increased. Conclusion IN opioids provide analgesic efficacy comparable to IV morphine at 20 and 30 minutes, with no clear increase in systemic adverse events. Larger trials should confirm safety for rare serious events and optimize dosing.

intravenous morphineanalgesic efficacyadverse eventsrescue analgesia
مراجعةمفتوح (مستودع)2026

Early Versus Late Initiation of High-Efficacy Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis

Annals of Middle Eastern Medicine

Background: Relapsing-remitting multiple sclerosis is a chronic immune-mediated disorder of the central nervous system associated with recurrent inflammatory activity and long-term disability accumulation. Although escalation therapy has traditionally been used, early initiation of high-efficacy disease-modifying therapies may provide stronger inflammatory control and improve long-term outcomes. Objective: This systematic review and meta-analysis aimed to compare early initiation of high-efficacy disease-modifying therapies with escalation or delayed treatment strategies in adults with relapsing-remitting multiple sclerosis. Methods: PubMed, Scopus, and Web of Science were systematically searched. Eligible studies included adults with relapsing-remitting multiple sclerosis treated with either early high-efficacy disease-modifying therapies or escalation/delayed strategies. Outcomes included annualized relapse rate, Expanded Disability Status Scale change, and delta-Expanded Disability Status Scale. Study quality was assessed using the Newcastle-Ottawa Scale, and pooled analyses were performed using random-effects models. Results: Ten observational cohort studies were included. Early initiation of high-efficacy treatment was associated with lower annualized relapse rate than escalation therapy. Disability findings remained uncertain. The pooled EDSS-change analysis was not statistically significant and showed considerable heterogeneity. Only one eligible study reported an adjusted delta-EDSS comparison; therefore, this outcome was reported narratively and was not meta-analyzed. Nonrandom treatment allocation and potential confounding by indication limit causal interpretation. Conclusion: Early initiation of high-efficacy disease-modifying therapy was associated with lower relapse activity in observational RRMS cohorts. The available disability evidence does not establish a causal advantage of either treatment strategy and requires cautious interpretation.

relapsing-remitting multiple sclerosisdisease-modifying therapyearly treatment initiationtreatment delay